Tag Archives: Labiotech.eu

UK’s Momentum Bio could help millions of hospital patients with first diagnostic test for blood infections that says whether or not to use antibiotics.

The News: Momentum Biosciences Ltd. (Cardiff UK) aims to pare back the unnecessary use of antimicrobial drugs in hospitals. To do this, it is developing molecular diagnostics that, within hours,… Read more »

Maat Pharma’s microbiome therapy shows early promise in cancer patients treatment. Are common gut bugs leading the charge to investment riches?

The News: A clinical trial run by MaaT Pharma SA (Lyon FRA) has shown that restoring the microbiome of patients undergoing chemotherapy has potential to improve the outcome of patients… Read more »

This Dutch biotech startup is quietly developing a novel immune-cell approach for cancer. Can it muscle in on established rivals?

The News: Lava Therapeutics BV (Hertogenbosch NLD) is quietly developing a cancer immunotherapy that arms a rare type of immune cell called gamma delta T cells, Labiotech.eu reports. The company’s… Read more »

Tissue engineering and regenerative medicine starting to elbow its way into media coverage; watch out you cancer “miracle cures.”

The News: A group of researchers in Spain has developed a silk biomaterial that can increase the survival of transplanted stem cells into the brain, improving recovery after a stroke… Read more »

Europe frets over waning IPO biotech scene while US pricings and new registrations keep chugging along.

The News: Over the last two weeks, several biotech companies in Europe have decided to postpone IPOs on the stock markets there prompting speculation that biotech stocks are underperforming, according… Read more »

England’s biotech startup Sitryx out of the blocks with new I/O program. Stakes are high as Europe’s science contending with US for top global developers.

The News: Sitryx Therapeutics Ltd. (London) has launched with the goal of treating cancer and inflammatory conditions by targeting the metabolism of immune cells, a promising new area of research…. Read more »

Europe bursts onto the biotech scene as Grifols’ Phase 2b/3 plasma replacement therapy works in Alzheimer’s patients. Buy, sell or hold?

The News: A blood plasma replacement therapy from Spanish company Grifols SA (Barcelona) reduced cognitive decline by 61% in patients with moderate Alzheimer’s disease compared with placebo, Labiotech.eu reports. The… Read more »

Why Galapagos’s Phase 3 rheumatoid arthritis success is largely irrelevant.

The News: Galapagos NV (Mechelen BEL) and Gilead Sciences Inc. (Foster City CA) have reported positive results from a Phase 3 trial testing Galapagos’s lead drug candidate in patients with… Read more »

UK-based Arecor targets vast artificial pancreas market with fast insulin and stable glucagon. Wait; artificial what?

The News: UK biotech Arecor Ltd. (Cambridge) has raised $7.8 million (€6.7M) to help fund development of its extra-fast insulin and stable glucagon products for people with insulin-dependent diabetes. The… Read more »

Novo Nordisk buys UK biotech startup for $800M, fueling blockbuster hopes for “smart” insulin. This Danish behemoth is a smart Buy.

The News: Novo Nordisk A/S (Bagsvaerd) has acquired UK start-up Ziylo Ltd. (Bristol) in a deal worth up to $800 million in a bid to develop the world’s first “smart”… Read more »